Sourced evidence
Iambic Therapeutics S-1/A (2026)
NVIDIA is a named platform partner of Iambic Therapeutics. Source extract: "Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer reflect meaningful external interest in our platform" Locator: Form S-1/A for period ended 2026-10-08, Business / Risk Factors.
- Type
- Company filing or release
- Published
- October 8, 2026
- Confidence
- 78/100
- Filed under
- NVIDIA
Supports these links
Cite this
InsightNodes, "Iambic Therapeutics S-1/A (2026)" (NVIDIA). Source: Iambic Therapeutics (SEC Form S-1/A), October 8, 2026, https://www.sec.gov/Archives/edgar/data/1997038/000119312526417416/iam-20261008.htm. https://insightnodes.com/claims/e/nvidia-iambic-therapeutics-partnership-s1a-2026 (accessed October 29, 2026).
This page has a permanent address — link to it from notes, articles or models. Not investment advice.